A revision of rapid colistin desensitization
Polymyxins, namely colistimethate sodium (colistin or polymyxin E) and polymyxin B, are used for multi-drug resistant gram-negative bacterial infections, including Pseudomonas aeruginosa and Acinetobacter baumannii 1. As treatments and therapy have advanced, patients with cystic fibrosis are living longer. However, these patients have high exposure to intravenous antibiotics, most commonly penicillins, cephalosporins, and aminoglycosides. With colonization or infections with resistant gram-negative bacilli, the exposure to antibiotics broadens to include the polymyxins.
ConclusionsFor closed-circuit dialysis using an RBC solution, the formula [dialysate flow rate (mL/min) × time of dialysis (min)]/extracorporeal volume (mL) would be a better parameter to estimate efficacy, compared with other metrics. Additionally, the citrate concentration can be readily estimated from the ionized calcium concentration during closed-circuit dialysis.
Condition: Asthma Interventions: Drug: Flamboyant 200/12; Drug: Budesonide / Formoterol 400/12; Other: Flamboyant 200/12 Placebo; Other: Budesonide / Formoterol 400/12 Placebo Sponsor: EMS Not yet recruiting
Condition: Asthma Interventions: Drug: Flamboyant 125/12; Drug: Budesonide/formoterol 200/6; Other: Flamboyant 125/12 Placebo; Other: Budesonide/formoterol 200/6 placebo Sponsor: EMS Not yet recruiting
Funding Opportunity PAR-20-072 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function system development and function; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics t...
Publication date: Available online 9 December 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Jörg Kleine-Tebbe, Claudia Mailänder
Publication date: Available online 9 December 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marta Vazquez-Ortiz, Laura Argiz, Adrianna Machinena, Luis Echeverria, Cristina Blasco, Ana Prieto, Sonsoles Infante, Leticia Vila, Emilio Garcia, Purificación Gonzalez-Delgado, Sonia Vazquez-Cortes, Simona Barni, Frederico Martinon-Torres, BIO-FPIES study network
Publication date: Available online 9 December 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yumiko Miyaji, Limin Yang, Kiwako Yamamoto-Hanada, Masami Narita, Hirohisa Saito, Yukihiro Ohya
Publication date: Available online 9 December 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Emily H. Liang, Lie H. Chen, Eric MacyAbstractBackgroundLimited population-based data on penicillin-, carbapenem-, monobactam-, and clindamycin-associated reported adverse reactions exists.ObjectiveCollect data on penicillin, carbapenem, monobactam, and clindamycin usage and associated adverse reactions.MethodsData from 1-1-2009 to 12-31-2017 in Kaiser Permanente Southern California was collected.ResultsThere were 6,144,422 unique individuals, mean age 33.6 ± 21.1 years, 52.2% females, with...
In conclusion, vitexin possess hepatoprotective activities against colitis-induced liver injury, it has potential application prospects in the treatment of liver injury induced by ulcerative colitis. PMID: 31810123 [PubMed - in process]
In conclusion, we proved that HLJDD-NBA fraction is an effective fraction of HLJDD in treating UC in mice, and it can maintain the intestinal flora homeostasis of UC mice, which increases our understanding of the mechanism of HLJDD in treating UC and lays a foundation for the development of new anti-ulcer drugs. PMID: 31810136 [PubMed - in process]